Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01791088 · ClinicalTrials.gov registry record · Phase 1
Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT01791088 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 56 participants.
The verdict
NCT01791088, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This clinical trial studies sirolimus in treating patients with solid tumors that are metastatic or cannot be removed by surgery. Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2012-06-13 |
| Est. Completion | 2018-08-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01791088
The ClinicalTrials.gov registry entry for NCT01791088 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01791088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01791088 about?
NCT01791088 is a clinical study titled "Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery". This clinical trial studies sirolimus in treating patients with solid tumors that are metastatic or cannot be removed by surgery. Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
What is the current status of trial NCT01791088?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2012-06-13. Estimated completion is 2018-08-17.
What interventions are being tested in trial NCT01791088?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), sirolimus (DRUG).
Who is sponsoring clinical trial NCT01791088?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.